Daily and Weekly Iron Supplementation in Infants

NCT ID: NCT06318858

Last Updated: 2024-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-15

Study Completion Date

2024-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Infants will be enrolled at 6 months and will be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months and will be followed by weekly iron supplementation for another 3 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to compare the efficacy of daily iron supplementation and weekly iron supplementation in infants aged 6-12 months on the prevalence of anemia, hemoglobin level, and serum ferritin levels. Normal birth weight and term infants will be enrolled at 6 months based on the inclusion criteria. Eligible participants will be assessed at baseline, including anthropometry, dietary intake, and biochemistry (hemoglobin, iron status, vitamin A status, and inflammation). Participants will then be randomly assigned to receive either daily or weekly iron supplementation for the first 3 months. Participants will be followed up at 9 months for the same assessments and will receive weekly iron supplementation for another 3 months. Participants will be followed up at 12 months and the same assessments will be performed. After that, participants will go back to the routine health care service, weekly iron supplementation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Iron Status Infants Iron

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

group 1: daily iron syrup supplementation group 2: weekly iron syrup supplementation
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
Letter codes were assigned to the iron syrup and the placebo by researchers who have not involved in the study. The codes have been kept until data analysis and report writing are complete.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 daily iron supplementation

12.5 mg daily iron syrup supplementation from 6-9 months old, followed by 12.5 mg weekly iron syrup supplementation from 9-12 months old.

Infants aged 6-9 months will receive two iron syrup bottles. One bottle aims for ingestion every Monday of the week, and one bottle aims for ingestion on other days of the week.

At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week.

Group Type EXPERIMENTAL

Iron supplement

Intervention Type DIETARY_SUPPLEMENT

Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old

Group 2 weekly iron supplementation

12.5 mg weekly iron syrup supplementation from 6-12 months old. Infants aged 6-9 months will receive an iron syrup bottle that aims for ingestion every Monday of the week and a placebo bottle that aims for ingestion on other days of the week.

At ages 9-12 months, infants will receive an iron syrup bottle that aims for ingestion every Monday of the week.

Group Type OTHER

Iron supplement

Intervention Type DIETARY_SUPPLEMENT

Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iron supplement

Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Apparently healthy infant, aged 6 months ± 2 weeks
* Having a birth weight between 2,500 and 4,000 grams
* Being born full term (37 to 41 weeks of age + 6 days)
* Having hemoglobin ≥ 10.5 g/dL
* Being planned to breastfeed with complementary food and/or complementary foods with formula milk

Exclusion Criteria

* Infants with chronic illnesses or thalassemia clinical signs such as anemia, enlarged liver, or spleen (if parental history suggests the child is at risk of developing a thalassemia disease that may not show clinical symptoms)
* Previously or currently taking an iron supplement
Minimum Eligible Age

6 Months

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Suranaree University of Technology

OTHER

Sponsor Role collaborator

Mahidol University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tippawan Pongcharoen, PhD

Role: PRINCIPAL_INVESTIGATOR

Mahidol University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samphran District Hospital

Sam Phran, Changwat Nakhon Pathom, Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tippawan Pongcharoen, PhD

Role: CONTACT

66813749901

Poonyanuch Chongjaroenjai, MD

Role: CONTACT

66899497799

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tinnakorn Chuenchom, MD

Role: primary

6634311021 ext. 105

Somchai Janelapwattanakul, MD

Role: backup

6634352052 ext. 4001

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MU-CIRB 2022/313.1411

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Healthy Infant Development Project
NCT00613717 COMPLETED NA